Norden Group LLC Acquires 3,582 Shares of Zoetis Inc. (NYSE:ZTS)

Norden Group LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 18.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,348 shares of the company’s stock after acquiring an additional 3,582 shares during the period. Norden Group LLC’s holdings in Zoetis were worth $3,804,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC boosted its stake in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in Zoetis during the third quarter worth about $31,000. First Personal Financial Services bought a new stake in Zoetis during the third quarter worth about $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis during the third quarter worth about $33,000. Finally, Dunhill Financial LLC boosted its stake in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.6 %

ZTS opened at $167.58 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a 50 day moving average price of $166.30 and a 200-day moving average price of $177.30. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The stock has a market capitalization of $75.04 billion, a price-to-earnings ratio of 30.64, a PEG ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.19%. Zoetis’s payout ratio is currently 36.56%.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ZTS shares. Piper Sandler lifted their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday. UBS Group started coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus decreased their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.